BioSpecifics Technologies Corp.  

(Public, NASDAQ:BSTC)   Watch this stock  
Find more results for Marc Guitman�
-0.36 (-0.87%)
Jul 22 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 40.80 - 41.62
52 week 30.70 - 72.07
Open 41.13
Vol / Avg. 13,565.00/40,154.00
Mkt cap 284.88M
P/E 29.50
Div/yield     -
EPS 1.39
Shares 7.02M
Beta 1.35
Inst. own 63%
Aug 8, 2016
Q2 2016 Biospecifics Technologies Corp Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Jun 9, 2016
Biospecifics Technologies Corp at Jefferies Healthcare Conference
May 31, 2016
Q1 2016 Biospecifics Technologies Corp Earnings Release
May 24, 2016
Biospecifics Technologies Corp at UBS Global Healthcare Conference
May 10, 2016
Q1 2016 Biospecifics Technologies Corp Earnings Call
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin 43.07% 42.28%
Operating margin 63.26% 63.49%
EBITD margin - 67.59%
Return on average assets 22.15% 25.07%
Return on average equity 24.56% 25.62%
Employees 5 -
CDP Score - -


LYNBROOK, NY 11563-2358
United States - Map
+1-516-5937000 (Phone)
+1-516-5937039 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


BioSpecifics Technologies Corp. (BioSpecifics) is a biopharmaceutical company. The Company is engaged in the development of an injectable collagenase clostridium histolyticum (CCH) for multiple indications. The Company has a development and license agreement with Endo International plc (Endo) for injectable collagenases for marketed indications and indications in development. CCH is marketed as XIAFLEX and as XIAPEX in Europe. Its injectable collagenases are marketed for indications, such as Dupuytren's contracture and Peyronie's disease. BioSpecifics is conducting development work with respect to human lipoma and uterine fibroids. XIAFLEX and XIAPEX are approved in the United States, the European Union, Switzerland, Canada, Australia and Japan for the treatment of Dupuytren's contracture. Endo manages the research and development of XIAFLEX for their licensed indications, including frozen shoulder, cellulite, canine lipoma, lateral hip fat, plantar fibromatosis and uterine fibroids.

Officers and directors

Thomas L. Wegman President, Principal Executive Officer, Principal Financial Officer, Director
Age: 60
Bio & Compensation  - Reuters
Mark N. Wegman Ph.D. Director
Age: 65
Bio & Compensation  - Reuters
Toby Wegman Director
Age: 80
Bio & Compensation  - Reuters
Jennifer M. Chao Independent Director
Age: 45
Bio & Compensation  - Reuters
Paul A. Gitman M.D. Independent Director
Age: 74
Bio & Compensation  - Reuters
George M. Gould J.D. Independent Director
Age: 77
Bio & Compensation  - Reuters